Liên Minh Châu Âu -
Tiếng Tây Ban Nha -
EMA (European Medicines Agency)
benlysta
glaxosmithkline (ireland) limited - belimumab - lupus eritematoso, sistémico - inmunosupresores - benlysta está indicado como complemento de la terapia en pacientes mayores de 5 años y más de edad activa, autoanticuerpos positivos lupus eritematoso sistémico (les) con un alto grado de actividad de la enfermedad (e. positivo anti-dsdna y complemento de baja) a pesar de la terapia estándar. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.
Liên Minh Châu Âu -
Tiếng Tây Ban Nha -
EMA (European Medicines Agency)
senshio
shionogi b.v. - ospemifeno - post menopausia - las hormonas sexuales y moduladores del sistema genital, - senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (vva) in post-menopausal women.
Liên Minh Châu Âu -
Tiếng Tây Ban Nha -
EMA (European Medicines Agency)
saphnelo
astrazeneca ab - anifrolumab - lupus eritematoso, sistémico - inmunosupresores - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.
Liên Minh Châu Âu -
Tiếng Tây Ban Nha -
EMA (European Medicines Agency)
lupkynis
otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - inmunosupresores - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).